We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer Joins Industry Chorus Challenging Exclusivity for FDCs
Bayer Joins Industry Chorus Challenging Exclusivity for FDCs
July 30, 2013
Bayer Healthcare has joined a growing chorus of drugmakers demanding the FDA revamp its regulations surrounding five-year exclusivity for fixed-dose combination (FDC) drugs.